Advertisement
Advertisement
June 9, 2026
FDA Approves CyndRx’s AbsorbaSeal Vascular Closure Device
KEY TAKEAWAYS
- FDA approves CyndRx’s AbsorbaSeal vascular closure device for acute arterial access site closure after catheter-based procedures.
- The company is moving toward United States commercialization for electrophysiology, interventional cardiology, vascular surgery, and interventional radiology in femoral arterial access.
June 9, 2026—CyndRx, LLC, announced FDA approval of its AbsorbaSeal vascular closure device. AbsorbaSeal is designed for acute arterial access site closure after catheter-based procedures.
CyndRx stated that with this approval, it will be advancing its United States commercialization efforts and engaging with stakeholders across electrophysiology, interventional cardiology, vascular surgery, and interventional radiology to support adoption of the technology for procedures requiring femoral arterial access.
According to the company, AbsorbaSeal is designed to reduce procedural complexity and provide a patient-friendly solution that avoids the use of permanent and collagen-based implants.
Interventional cardiologist Vishal Gupta, MD, commented in the company’s press release, “As a clinical investigator in the SEAL TO HEAL trial, I saw AbsorbaSeal deliver on the priorities that matter most to interventionalists regarding vascular access closure: reliable hemostasis, early ambulation, and no permanent implant left behind.”
Dr. Gupta added, “I believe AbsorbaSeal has the potential to set a new benchmark for femoral access closure, benefiting patients, operators, and health systems alike.”
Advertisement
Advertisement
